William Blair Brokers Cut Earnings Estimates for Medtronic plc (NYSE:MDT)

Medtronic plc (NYSE:MDT) – William Blair lowered their Q3 2025 EPS estimates for shares of Medtronic in a research note issued on Wednesday, August 21st. William Blair analyst M. Kaczor now expects that the medical technology company will earn $1.37 per share for the quarter, down from their prior estimate of $1.38. The consensus estimate for Medtronic’s current full-year earnings is $5.44 per share.

Several other equities research analysts have also recently issued reports on MDT. The Goldman Sachs Group began coverage on shares of Medtronic in a research report on Thursday, May 30th. They set a “sell” rating and a $83.00 price objective for the company. Citigroup dropped their price target on shares of Medtronic from $90.00 to $85.00 and set a “neutral” rating for the company in a research note on Wednesday, July 10th. UBS Group raised shares of Medtronic from a “sell” rating to a “neutral” rating and lifted their price target for the company from $76.00 to $90.00 in a research report on Thursday, August 15th. Wells Fargo & Company upped their price objective on Medtronic from $105.00 to $106.00 and gave the company an “overweight” rating in a report on Wednesday. Finally, Stifel Nicolaus raised their target price on Medtronic from $85.00 to $87.00 and gave the stock a “hold” rating in a research note on Wednesday. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $92.54.

Medtronic Stock Up 0.4 %

NYSE MDT opened at $87.86 on Friday. The business’s fifty day simple moving average is $80.33 and its 200-day simple moving average is $82.34. The company has a quick ratio of 1.55, a current ratio of 2.03 and a debt-to-equity ratio of 0.47. The firm has a market cap of $112.66 billion, a PE ratio of 31.95, a P/E/G ratio of 2.35 and a beta of 0.82. Medtronic has a 52 week low of $68.84 and a 52 week high of $89.24.

Medtronic (NYSE:MDT) last announced its quarterly earnings data on Tuesday, August 20th. The medical technology company reported $1.23 EPS for the quarter, topping analysts’ consensus estimates of $1.20 by $0.03. The firm had revenue of $7.97 billion for the quarter, compared to the consensus estimate of $7.90 billion. Medtronic had a return on equity of 13.47% and a net margin of 11.36%. The firm’s revenue was up 3.4% compared to the same quarter last year. During the same quarter last year, the business posted $1.20 earnings per share.

Medtronic Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 11th. Investors of record on Friday, September 27th will be issued a $0.70 dividend. The ex-dividend date is Friday, September 27th. This represents a $2.80 annualized dividend and a dividend yield of 3.19%. Medtronic’s dividend payout ratio is presently 101.82%.

Insider Buying and Selling

In other Medtronic news, CEO Geoffrey Martha sold 19,113 shares of Medtronic stock in a transaction dated Friday, June 7th. The stock was sold at an average price of $83.77, for a total value of $1,601,096.01. Following the completion of the transaction, the chief executive officer now directly owns 143,348 shares of the company’s stock, valued at approximately $12,008,261.96. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 0.30% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Medtronic

A number of hedge funds have recently added to or reduced their stakes in the business. MeadowBrook Investment Advisors LLC acquired a new position in shares of Medtronic in the fourth quarter worth $27,000. LifeSteps Financial Inc. purchased a new position in Medtronic in the first quarter valued at $27,000. Lynx Investment Advisory purchased a new stake in Medtronic during the 2nd quarter worth about $28,000. Tributary Capital Management LLC acquired a new position in shares of Medtronic during the first quarter worth about $33,000. Finally, Fortis Group Advisors LLC increased its stake in shares of Medtronic by 100.0% during the fourth quarter. Fortis Group Advisors LLC now owns 460 shares of the medical technology company’s stock worth $38,000 after buying an additional 230 shares during the period. 82.06% of the stock is currently owned by institutional investors and hedge funds.

About Medtronic

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.